Factors Associated with Antidepressant Medication Non-adherence

Marasine, Nirmal Raj; Sankhi, Sabina

doi:10.4274/tjps.galenos.2020.49799

Cited by 31 publications

(20 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are differences in the impact of necessity beliefs and concern beliefs on therapeutic compliance in different studies. Most studies have shown that necessity beliefs were positively correlated with higher medication compliance while concern beliefs were positively correlated with poor compliance of patients [ 16 , 34 – 36 ]. High medication compliance is correlated with the improvement of depressive symptoms in some patients.…”

Section: Discussionmentioning

confidence: 99%

Baseline beliefs about medication are associated with outcomes of antidepressants in inpatients with first-diagnosed depression under supervised therapeutic compliance

Kong

et al. 2021

Aging

View full text Add to dashboard Cite

The aim of the present study was to explore the effect of baseline beliefs about medication on therapeutic outcomes of antidepressants in inpatients with first-diagnosed depression under supervised therapeutic compliance. Ninety-seven inpatients with first-diagnosed depression were included to collect their baseline demographic data to evaluate the Hamilton depression rating scale (HAMD) scores and the beliefs about medicine questionnaire-specific (BMQ-S) scores at baseline and the end of the eight-week treatment. Additionally, we explored the relationship between inpatients’ medication beliefs and therapeutic effect of antidepressants. The inpatients were divided into remitted depression and unremitted depression groups according to outcomes at the end of the eight-week treatment. There was no significant difference in the baseline HAMD between the two groups ( P > 0.050). The scores on the BMQ-S of the unremitted group were significantly lower than those of the remitted group ( P < 0.001). The HAMD scores were significantly reduced in both groups after the eight-week treatment ( P < 0.001). There was no significant difference in the BMQ-S scores before and after the treatment ( P > 0.050). The medication beliefs of the unremitted inpatients after the treatment were still lower than those of the remitted inpatients ( P < 0.001). Logistic-regression analysis showed that low BMQ-S scores at the baseline were an independent risk factor for antidepressant efficacy. Beliefs about medication at baseline may be correlated with the therapeutic efficacy in inpatients with first-diagnosed depression under supervised therapeutic compliance.

show abstract

Section: Discussionmentioning

confidence: 99%

Baseline beliefs about medication are associated with outcomes of antidepressants in inpatients with first-diagnosed depression under supervised therapeutic compliance

Kong

et al. 2021

Aging

View full text Add to dashboard Cite

show abstract

“…Previous studies have reported that a significant proportion of individuals with MDD, ranging from 60.0–70.0%, have poor medication adherence [ 7 , 8 ]. Understanding MDD and its treatment may have a significant impact on adherence to antidepressants [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Knowledge and attitudes on medication adherence and residual symptoms in individuals with depression: a survey at a University Hospital

Pitanupong

Sammathit

2023

BMC Psychiatry

View full text Add to dashboard Cite

Background Depression is a common disease and the relapse of depression can cause functional impairment. Good medication adherence and relapse prevention should be targeted to achieve normal functioning. This study aimed to evaluate the levels of knowledge, attitude toward depression, and medication adherence among individuals with depression. Methods A cross-sectional study surveyed Thai individuals with depression at the psychiatric outpatient clinic of Songklanagarind Hospital; from April to August 2022. The questionnaires inquired about:1) demographic information, 2) knowledge and attitude toward depression questionnaire, 3) the medication adherence scale in Thais (MAST), 4) the Patient Health Questionnaire-9 (PHQ-9), 5) the stigma questionnaire, 6) a patient-doctor relationship questionnaire (PDRQ-9), and 7) the Revised Thai Multidimensional Scale of Perceived Social Support (rMSPSS). All data were analyzed using descriptive statistics. Chi-square or Fisher’s exact test, and Wilcoxon rank sum test were used. Results Of all 264 participants, the majority of them were female (78.4%). The overall mean age was 42.3 ± 18.3 years. Most participants had good knowledge and a positive attitude regarding any relationship problems, childhood trauma or bad memories, or having a chemical imbalance in the brain as one of the main causes that result in depression (86.4, 82.6, 77.3%, respectively). They disagreed with common stereotypical assumptions towards individuals with depression. Most of them had good medication adherence (97.0%), low or no level of stigma (92.5%), high perceived social support from family (64.4%), and good doctor-patient relationships (82.2%). Due to most participants reporting having good medication adherence, then an attempt to indicate the factors associated with medication adherence could not be established in this study. This study found that individuals reporting residual symptoms of depression had higher levels of knowledge and perceived stigma, but lower levels of family support compared to those without residual symptoms. Conclusion Most participants reported good knowledge and a positive attitude toward depression. They exhibited good medication adherence, a low level of stigma, and a high level of social support. This study revealed a correlation between the presence of residual symptoms of depression and increased levels of knowledge, perceived stigma, and reduced family support.

show abstract

“…In the management of depression, the average response rate reported for antidepressants ranged from 42% to 53% ( Cipriani et al, 2018a ; Cipriani et al, 2018b ), while nearly 50% of patients experienced adverse reactions (ADRs) during treatment ( Braund et al, 2021 ). ADRs and ineffectiveness are a major contributor towards poor adherence and discontinuation of antidepressants ( Marasine and Sankhi, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses

et al. 2023

View full text Add to dashboard Cite

Pharmacogenetics has potential for optimizing use of psychotropics. CYP2D6 and CYP2C19 are two clinically relevant pharmacogenes in the prescribing of antidepressants. Using cases recruited from the Understanding Drug Reactions Using Genomic Sequencing (UDRUGS) study, we aimed to evaluate the clinical utility of genotyping CYP2D6 and CYP2C19 in antidepressant response. Genomic and clinical data for patients who were prescribed antidepressants for mental health disorders, and experienced adverse reactions (ADRs) or ineffectiveness, were extracted for analysis. Genotype-inferred phenotyping of CYP2D6 and CYP2C19 was carried out as per Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines. A total of 52 patients, predominantly New Zealand Europeans (85%) with a median age (range) of 36 years (15–73), were eligible for analysis. Thirty-one (60%) reported ADRs, 11 (21%) ineffectiveness, and 10 (19%) reported both. There were 19 CYP2C19 NMs, 15 IMs, 16 RMs, one PM and one UM. For CYP2D6, there were 22 NMs, 22 IMs, four PMs, three UMs, and one indeterminate. CPIC assigned a level to each gene-drug pair based on curated genotype-to-phenotype evidence. We analyzed a subgroup of 45 cases, inclusive of response type (ADRs/ineffectiveness). Seventy-nine (N = 37 for CYP2D6, N = 42 for CYP2C19) gene-drug/antidepressant-response pairs with CPIC evidence levels of A, A/B, or B were identified. Pairs were assigned as ‘actionable’ if the CYP phenotypes potentially contributed to the observed response. We observed actionability in 41% (15/37) of CYP2D6-antidepressant-response pairs and 36% (15/42) of CYP2C19-antidepressant-response pairs. In this cohort, CYP2D6 and CYP2C19 genotypes were actionable for a total of 38% pairs, consisting of 48% in relation to ADRs and 21% in relation to drug ineffectiveness.

show abstract

Factors Associated with Antidepressant Medication Non-adherence

Cited by 31 publications

References 43 publications

Baseline beliefs about medication are associated with outcomes of antidepressants in inpatients with first-diagnosed depression under supervised therapeutic compliance

Baseline beliefs about medication are associated with outcomes of antidepressants in inpatients with first-diagnosed depression under supervised therapeutic compliance

Knowledge and attitudes on medication adherence and residual symptoms in individuals with depression: a survey at a University Hospital

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses

Contact Info

Product

Resources

About